Advances in the orthopedic management of osteogenesis imperfecta

Orthopedic Clinics of North America

Volumn 44, Issue 4, 2013, Pages 565-573

  Laron, Dominique ^a   Pandya, Nirav K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Advances; Bisphosphonates; Intramedullary fixation; Medical; Orthopedic; Osteogenesis imperfecta; Surgical

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLLAGEN TYPE 1; GROWTH HORMONE; NERIDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TELESCOPIC IM SYSTEM; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE MALFORMATION; CHILD HEALTH CARE; DNA DETERMINATION; FETUS ECHOGRAPHY; FRACTURE; FRACTURE FIXATION; GENE MUTATION; GENETIC DISORDER; HUMAN; ORTHOPEDIC FIXATION DEVICE; ORTHOPEDIC SURGERY; OSTEOGENESIS IMPERFECTA; PERINATAL PERIOD; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN BIOPSY; SYSTEMATIC REVIEW (TOPIC); UNSPECIFIED SIDE EFFECT;

ADVANCES; BISPHOSPHONATES; INTRAMEDULLARY FIXATION; MEDICAL; ORTHOPEDIC; OSTEOGENESIS IMPERFECTA; SURGICAL;

HUMANS; OSTEOGENESIS IMPERFECTA;

EID: 84884980085     PISSN: 00305898     EISSN: 15581373     Source Type: Journal    
DOI: 10.1016/j.ocl.2013.06.010     Document Type: Review

References (56)

1. Peltier L.F. The classic: congenital osteomalacia. Olaus Jacob Ekman. Clin Orthop Relat Res 1981, (159):3-5.
2. Baljet B. Aspects of the history of osteogenesis imperfecta (Vrolik's syndrome). Ann Anat 2002, 184:1-7.
3. Baljet B. Willem Vrolik as a teratologist. Ned Tijdschr Geneeskd 1984, 128:1530-1534. [in Dutch].
4. Sillence D.O., Senn A., Danks D.M. Genetic heterogeneity in osteogenesis imperfecta. JMed Genet 1979, 16:101-116.
5. Teitelbaum S.L., Kraft W.J., Lang R., et al. Bone collagen aggregation abnormalities in osteogenesis imperfecta. Calcif Tissue Res 1974, 17:75-79.
6. Barsh G.S., David K.E., Byers P.H. Type I osteogenesis imperfecta: a nonfunctional allele for pro alpha 1 (I) chains of type I procollagen. Proc Natl Acad Sci U S A 1982, 79:3838-3842.
7. Chu M.L., Williams C.J., Pepe G., et al. Internal deletion in a collagen gene in a perinatal lethal formof osteogenesis imperfecta. Nature 1983, 304:78-80.
8. Wallis G.A., Sykes B., Byers P.H., et al. Osteogenesis imperfecta type III: mutations in the type I collagen structural genes, COL1A1 and COL1A2, are not necessarily responsible. JMed Genet 1993, 30:492-496.
9. Morello R., Bertin T.K., Chen Y., et al. CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell 2006, 127:291-304.
10. Cabral W.A., Chang W., Barnes A.M., et al. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat Genet 2007, 39:359-365.
11. Barnes A.M., Carter E.M., Cabral W.A., et al. Lack of cyclophilin B in osteogenesis imperfecta with normal collagen folding. NEngl J Med 2010, 362:521-528.
12. Christiansen H.E., Schwarze U., Pyott S.M., et al. Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta. Am J Hum Genet 2010, 86:389-398.
13. Becker J., Semler O., Gilissen C., et al. Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am J Hum Genet 2011, 88:362-371.
14. Ha-Vinh R., Alanay Y., Bank R.A., et al. Phenotypic and molecular characterization of Bruck syndrome (osteogenesis imperfecta with contractures of the large joints) caused by a recessive mutation in PLOD2. Am J Med Genet A 2004, 131:115-120.
15. Alanay Y., Avaygan H., Camacho N., et al. Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta. Am J Hum Genet 2010, 86:551-559.
16. Gong Y., Slee R.B., Fukai N., et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001, 107:513-523.
17. Lapunzina P., Aglan M., Temtamy S., et al. Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta. Am J Hum Genet 2010, 87:110-114.
18. van Dijk F.S., Byers P.H., Dalgleish R., et al. EMQN best practice guidelines for the laboratory diagnosis of osteogenesis imperfecta. Eur J Hum Genet 2012, 20:11-19.
19. Tsai P.Y., Chang C.H., Yu C.H., et al. Three-dimensional ultrasound in the prenatal diagnosis of osteogenesis imperfecta. Taiwan J Obstet Gynecol 2012, 51:387-392.
20. Viora E., Sciarrone A., Bastonero S., et al. Increased nuchal translucency in the first trimester as a sign of osteogenesis imperfecta. Am J Med Genet 2002, 109:336-337.
21. Morgan J.A., Marcus P.S. Prenatal diagnosis and management of intrauterine fracture. Obstet Gynecol Surv 2010, 65:249-259.
22. Marini J.C., Forlino A., Cabral W.A., et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat 2007, 28:209-221.
23. Körkkö J., Annunen S., Pihlajamaa T., et al. Conformation sensitive gel electrophoresis for simple and accurate detection of mutations: comparison with denaturing gradient gel electrophoresis and nucleotide sequencing. Proc Natl Acad Sci U S A 1998, 95:1681-1685.
24. Bodian D.L., Chan T.F., Poon A., et al. Mutation and polymorphism spectrum in osteogenesis imperfecta type II: implications for genotype-phenotype relationships. Hum Mol Genet 2009, 18:463-471.
25. Phillipi C.A., Remmington T., Steiner R.D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 2008, (4). CD005088.
26. Castillo H., Samson-Fang L., American Academy for Cerebral Palsy and Developmental Medicine Treatment Outcomes Committee Review Panel Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review. Dev Med Child Neurol 2009, 51:17-29.
27. Sakkers R., Kok D., Engelbert R., et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 2004, 9419:1427-1431.
28. Ward L.M., Rauch F., Whyte M.P., et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. JClin Endocrinol Metab 2011, 96:355-364.
29. Barros E.R., Saraiva G.L., de Oliveira T.P., et al. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. JPediatr Endocrinol Metab 2012, 25(5-6):485-491.
30. DiMeglio L.A., Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. JBone Miner Res 2006, 21:132-140.
31. Antoniazzi F., Monti E., Venturi G., et al. GH in combination with bisphosphonate treatment in osteogenesis imperfecta. Eur J Endocrinol 2010, 163:479-487.
32. de Graaff F., Verra W., Pruijs J., et al. Decrease in outpatient department visits and operative interventions due to bisphosphonates in children with osteogenesis imperfecta. JChild Orthop 2011, 5:121-125.
33. Kok D.H., Sakkers R.J., Janse A.J., et al. Quality of life in children with osteogenesis imperfecta treated with oral bisphosphonates (Olpadronate): a 2-yearrandomized placebo-controlled trial. Eur J Pediatr 2007, 166:1155-1161.
34. Antoniazzi F., Zamboni G., Lauriola S., et al. Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. JPediatr 2006, 149:174-179.
35. Rauch F., Munns C.F., Land C., et al. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. JBone Miner Res 2009, 24:1282-1289.
36. Sofield H.A., Millar E.A. Fragmentation, realignment, and intramedullary rod fixation of deformities of the long bones in children: a ten year appraisal. JBone Joint Surg Am 1959, 41:1371-1391.
37. Abulsaad M., Abdelrahman A. Modified Sofield-Millar operation: less invasive surgery of lower limbs in osteogenesis imperfecta. Int Orthop 2009, 33:527-532.
38. Li Y.H., Chow W., Leong J.C. The Sofield-Millar operation in osteogenesis imperfecta. A modified technique. JBone Joint Surg Br 2000, 82:11-16.
39. Khoshhal K.I., Ellis R.D. Effect of lower limb Sofield procedure on ambulation in osteogenesis imperfecta. JPediatr Orthop 2001, 21:233-235.
40. Dal Monte A., Manes E., Capanna R., et al. Osteogenesis imperfecta: results obtained with the Sofield method of surgical treatment. Ital J Orthop Traumatol 1982, 8:43-52.
41. Bailey R.W., Dubow H.I. Studies of longitudinal bone growth resulting in an extensible nail. Surg Forum 1963, 14:455-458.
42. Bailey R.W. Further clinical experience with the extensible nail. Clin Orthop Relat Res 1981, (159):171-176.
43. Lang-Stevenson A.I., Sharrard W.J. Intramedullary rodding with Bailey-Dubow extensible rods in osteogenesis imperfecta. An interim report of results and complications. JBone Joint Surg Br 1984, 66:227-232.
44. Jerosch J., Mazzotti I., Tomasevic M. Complications after treatment of patients with osteogenesis imperfecta with a Bailey-Dubow rod. Arch Orthop Trauma Surg 1998, 117:240-245.
45. Gamble J.G., Strudwick W.J., Rinsky L.A., et al. Complications of intramedullary rods in osteogenesis imperfecta: Bailey-Dubow rods versus nonelongating rods. JPediatr Orthop 1988, 8:645-649.
46. Stockley I., Bell M.J., Sharrard W.J. The role of expanding intramedullary rods in osteogenesis imperfecta. JBone Joint Surg Br 1989, 71:422-427.
47. Wilkinson J.M., Scott B.W., Clarke A.M., et al. Surgical stabilisation of the lower limb in osteogenesis imperfecta using the Sheffield Telescopic Intramedullary Rod System. JBone Joint Surg Br 1998, 80:999-1004.
48. Nicolaou N., Bowe J.D., Wilkinson J.M., et al. Use ofthe Sheffield telescopic intramedullary rod system for the management of osteogenesis imperfecta: clinical outcomes at an average follow-up of nineteen years. JBone Joint Surg Am 2011, 93:1994-2000.
49. Fassier F, Duval P. New concept for telescoping rodding in osteogenesis imperfecta: preliminary results. In: Proceedings of the Annual Meeting of the Pediatric Orthopaedic Society of North America (POSNA). Cancun (Mexico): 2001.
50. Fassier F, Esposito P, Sponsellor P, etal. Multicenter radiological assessment of the Fassier-Duval femoral rodding. In: Proceedings of the Annual Meeting of the Pediatric Orthopaedic Society of North America (POSNA). San Diego (CA): 2006.
51. Fassier F, Halloran JP, Allam N. Fassier-Duval tibial rodding in patients with osteogenesis imperfecta. In: Proceedings of the Annual Meeting of the Pediatric Orthopaedic Society of North America (POSNA). Waikoloa (HI): 2010.
52. Birke O., Davies N., Latimer M., et al. Experience with the Fassier-Duval telescopic rod: first 24 consecutive cases with a minimum of 1-year follow-up. JPediatr Orthop 2011, 31:458-464.
53. Ruck J., Dahan-Oliel N., Montpetit K., et al. Fassier-Duval femoral rodding in children with osteogenesis imperfecta receiving bisphosphonates: functional outcomes at one year. JChild Orthop 2011, 5:217-224.
54. Munns C., Rauch F., Zeitlin L., et al. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. JBone Miner Res 2004, 19:1779-1786.
55. Pizones J., Plotkin H., Parra-Garcia J., et al. Bone healing in children with osteogenesis imperfecta treated with bisphosphonates. JPediatr Orthop 2005, 25:332-335.
56. El Sobky M., Zaky H., Atef A., et al. Surgery versus surgery plus pamidronate in the management of osteogenesis imperfecta patients: a comparative study. JPediatr Orthop B 2006, 15:222-228.